Nephrodite’s HollyTM Implantable Continuous Dialysis System Awarded Selection into FDA’s TAP to Accelerate Development and Patient Access

ATLANTA--(BUSINESS WIRE)--Nephrodite, Inc., a medical device company developing an implantable, continuous renal replacement system, today announced that its HollyTM system has been selected to participate in TAP by the U.S. Food and Drug Administration (FDA). “We are dedicated to moving our technology as quickly and safely as possible into healthcare systems for eligible patients with end-stage kidney disease to stop the burden of three-times-weekly, clinic-based dialysis and improve their phys